Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Topotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 19/20 | 0.98 |
| ▸ | MEN1 | O00255 | 5/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.98 |
| ▸ | CASP1 | P29466 | 3/20 | 0.98 |
| ▸ | CASP7 | P55210 | 3/20 | 0.98 |
| ▸ | HBB | P68871 | 3/20 | 0.98 |
| ▸ | MAPT | P10636 | 3/20 | 0.98 |
| ▸ | USP2 | O75604 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.98 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.98 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.97 |
| ▸ | TOP2A | P11388 | 1/20 | 0.97 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.97 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Topotecan SCHEMBL27780077 | 1.00 | TOP1 (0.98) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL5959100 | 1.00 | TOP1 (0.98) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL13731135 | 1.00 | TOP1 (0.98) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL29375999 | 0.99 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL7247 | 0.99 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL10278 | 0.99 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL7248 | 0.99 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL418714 | 0.99 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL10588295 | 0.99 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL29742318 | 0.99 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158645-B2 | Compound, corresponding compositions, preparation and/or treatment methods | GLAXOSMITHKLINE LLC (US) | 2012-04-17 | — | — | US | claimed |
| US-20100210677-A1 | NOVEL COMPOUND, CORRESPONDING COMPOSITIONS, PREPARATION AND/OR TREATMENT METHODS | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | claimed |
| US-7754733-B2 | Crystalline topotecan hydrochloride product and process for making the same | GLAXOSMITHKLINE LLC (US) | 2010-07-13 | — | — | US | claimed |
| US-20070117832-A1 | Novel compound, corresponding compositons, preparation and/or treatment methods | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-24 | — | — | US | claimed |
| JP-2007510751-A | — | — | 2007-04-26 | — | — | JP | claimed |
| EP-1689400-A4 | NOVEL COMPOUND, CORRESPONDING COMPOSITIONS, PREPARATION AND/OR TREATMENT METHODS | SMITHKLINE BEECHAM CORP (US) | 2006-12-27 | — | — | EP | claimed |
| EP-1689400-A2 | NOVEL COMPOUND, CORRESPONDING COMPOSITIONS, PREPARATION AND/OR TREATMENT METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-16 | — | — | EP | claimed |
| WO-2005046608-A2 | NOVEL COMPOUND, CORRESPONDING COMPOSITIONS, PREPARATION AND/OR TREATMENT METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-05-26 | — | — | WO | claimed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-2139899-B1 | CRYSTALLINE FORMS OF TOPOTECAN HYDROCHLORIDE AND PROCESSES FOR MAKING THE SAME | SCINOPHARM TAIWAN LTD (TW) | 2016-10-19 | — | — | EP | disclosed |
| US-8349863-B2 | Crystalline polymorphic form of a camptothecin analogue | CIPLA LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| US-8158645-B2 | Compound, corresponding compositions, preparation and/or treatment methods | GLAXOSMITHKLINE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158645-B2 | Compound, corresponding compositions, preparation and/or treatment methods | GLAXOSMITHKLINE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1689400-A2 | NOVEL COMPOUND, CORRESPONDING COMPOSITIONS, PREPARATION AND/OR TREATMENT METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1689400-A2 | NOVEL COMPOUND, CORRESPONDING COMPOSITIONS, PREPARATION AND/OR TREATMENT METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005046608-B1 | NOVEL COMPOUND, CORRESPONDING COMPOSITIONS, PREPARATION AND/OR TREATMENT METHODS | SMITHKLINE BEECHAM CORP (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005046608-A3 | NOVEL COMPOUND, CORRESPONDING COMPOSITIONS, PREPARATION AND/OR TREATMENT METHODS | SMITHKLINE BEECHAM CORP (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005046608-A2 | NOVEL COMPOUND, CORRESPONDING COMPOSITIONS, PREPARATION AND/OR TREATMENT METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005046608-A2 | NOVEL COMPOUND, CORRESPONDING COMPOSITIONS, PREPARATION AND/OR TREATMENT METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | TOP1 3/4885MEN1 601/4885KMT2A 1727/4885 |
| US-20100210677-A1 | NOVEL COMPOUND, CORRESPONDING COMPOSITIONS, PREPARATION AND/OR TREATMENT METHODS | TOP2A, TOP1, TOP2B | TOP1 2/4885MEN1 756/4885KMT2A 617/4885 |
| US-20070117832-A1 | Novel compound, corresponding compositons, preparation and/or treatment methods | TOP2A, TYMS, TOP1 | TOP1 3/4885MEN1 472/4885KMT2A 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.